Develops therapies for oral mucositis and other oral diseases, focusing on probiotics and antibiotics.
Oragenics, Inc. is at the forefront of developing innovative antibiotics to combat infectious diseases within the United States. The company focuses on advancing a diverse pipeline of promising product candidates aimed at addressing critical healthcare needs. Among its notable developments are NT-CoV2-1 and Terra CoV-2, both vaccine candidates designed to confer immunity against the severe acute respiratory syndrome coronavirus. NT-CoV2-1 is administered intranasally, while Terra CoV-2 is given intramuscularly, reflecting Oragenics' commitment to providing versatile solutions for pandemic preparedness.
In addition to its vaccine initiatives, Oragenics, Inc. is actively pursuing therapeutic advancements beyond infectious diseases. Its product portfolio includes LPT3-04, a candidate targeted at weight loss, and SMaRT Replacement Therapy, a topical treatment designed to prevent dental caries. These efforts underscore the company's dedication to leveraging cutting-edge research and development to address diverse health challenges effectively. Oragenics, Inc. collaborates extensively within the biopharmaceutical sector, evident through partnerships with entities like Noachis Terra Inc., focusing on licensing specific patent rights related to coronavirus spike proteins, and collaborations with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs.
Founded in 1996 and headquarted in Tampa, Florida, Oragenics, Inc. operates within a dynamic biotechnology landscape. The company's location positions it strategically within a thriving biomedical community, fostering collaboration and innovation in the pursuit of groundbreaking medical solutions. With a robust pipeline and strategic partnerships, Oragenics, Inc. continues to advance its mission of improving public health through the development of innovative therapies and vaccines.